Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304794 | 0.76 | KMT2A (0.41) | KMT2AKIF11ACLYPIK3CDNPC1 | |
| Hydrochloric Acid SCHEMBL27646829 | 0.74 | KMT2A (0.40) | KMT2AKIF11ACLYPIK3CDNPC1 | |
| SCHEMBL23959147 | 0.73 | KIF11 (0.41) | KMT2AKIF11ACLYPIK3CDKDM4E | |
| Hydrochloric Acid SCHEMBL29776090 | 0.72 | KIF11 (0.40) | KMT2AKIF11ACLYPIK3CDKDM4E | |
| SCHEMBL1540045 | 0.72 | LCK (0.50) | KMT2ASMN1; SMN2 | |
| SCHEMBL6404488 | 0.71 | LCK (0.33) | KIF11GRM5 | |
| SCHEMBL30194928 | 0.71 | HRH4 (0.38) | KMT2AKIF11ACLYPIK3CD | |
| SCHEMBL30237770 | 0.69 | DPP4 (0.35) | KMT2AKIF11ACLYPIK3CDNPC1 | |
| SCHEMBL23959384 | 0.68 | KIF11 (0.50) | KMT2AKIF11PIK3CDNPC1HPGD | |
| Methyl Alcohol SCHEMBL28357518 | 0.68 | KMT2A (0.43) | KMT2ADAOPIK3CDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | DAS JAGABANDHU (US) | 2004-04-22 | — | — | US | claimed |
| WO-2010120388-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | JAK1, LCK, MERTK | S1PR4 1763/4885KMT2A 423/4885GPBAR1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.